Skip to Content
Merck
CN

Acid-Activated Melittin for Targeted and Safe Antitumor Therapy.

Bioconjugate chemistry (2018-08-28)
Li Luo, Wei Wu, Da Sun, Han-Bin Dai, Yi Wang, Yuan Zhong, Jin-Xuan Wang, Ali Maruf, Deti Nurhidayah, Xiao-Juan Zhang, Ying Wang, Gui-Xue Wang
ABSTRACT

Melittin (MLT), as a natural active biomolecule, can penetrate the tumor cell membrane to play a role in cancer treatment and will attract more attention in future development of antitumor drugs. The main component of natural bee venom MLT was modified by introducing a pH-sensitive amide bond between the 2,3-dimethyl maleimide (DMMA) and the lysine (Lys) of MLT (MLT-DMMA). MLT and its corresponding modified peptide MLT-DMMA were used for antitumor and biocompatibility validation. The biomaterial characteristics were tested by MALDI-TOF MS, 1H NMR, IUPAC and HPLC, cell viability, hemolytic and animal experiment safety evaluation. Compared with the primary melittin, the modified peptide showed decreased surface charge and low cytotoxicity in physiological conditions. Moreover, cell assays confirmed the acid-activated conversion of amide bond resulting in adequate safety during delivery and timely antitumor activity in tumor lesions. Thus, MLT-DMMA provided a feasible platform to improve the targeted and safe antitumor applications.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethyl 3-aminobenzoate methanesulfonate, 98%
Sigma-Aldrich
Maleimide, 99%